Inhibition of injury-induced glial aromatase reveals a wave of secondary degeneration in the songbird brain.
Mechanical or anoxic/ischemic brain insult results in reactive gliosis and a pronounced wave of apoptotic secondary degeneration (WSD). Reactive glia express aromatase (estrogen synthase) and glial estrogen synthesis decreases apoptosis and the volume of degeneration. Whether aromatization by glia affects gliosis itself or the initiation/maintenance of the WSD remains unknown. Adult male zebra finches (Taeniopygia guttata) were injured with a needle that contained the aromatase inhibitor fadrozole or vehicle into contralateral hemispheres. Birds were killed at 0, 2, 6, 24, 72h, 2 or 6 weeks postinjury. Gliosis and degeneration were measured with vimentin- and Fluoro-Jade B-expression, respectively. Reactive gliosis was detectable at 6 h, reached asymptote at 72 h, and continued until 6 weeks postinsult. Gliosis extended further around fadrozole-injury than vehicle, an effect driven by a larger area of gliosis around fadrozole- relative to vehicle-injury at 72 h postinsult. Glial aromatase was inhibited for about 2 weeks postinjury since aromatase relative optical density was higher around fadrozole-injury relative to vehicle-injury until this time-point. Degeneration around vehicle-injury reached asymptote at 2 h postinsult, but that around fadrozole-injury peaked 24-72 h postinjury and decreased thereafter. Thus, the injury-induced WSD as described in mammals is detectable in zebra finches only following glial aromatase inhibition. In the zebra finch, injury-induced estrogen provision may decrease reactive gliosis and severely dampen the WSD, suggesting that songbirds are powerful models for understanding the role of glial aromatization in secondary brain damage.
Wynne
Ryan D
RD
Department of Biological Sciences, Lehigh University, Bethlehem, Pennsylvania 18015, USA.
Walters
Bradley J
BJ
Bailey
David J
DJ
Saldanha
Colin J
CJ
D000818:Animals; D017209:Apoptosis / Q000187:drug effects / Q000502:physiology; D001141:Aromatase / Q000096:biosynthesis*; D047072:Aromatase Inhibitors / Q000494:pharmacology*; D001921:Brain / Q000201:enzymology / Q000473:pathology*; D003627:Data Interpretation, Statistical; D004791:Enzyme Inhibitors / Q000494:pharmacology; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D017316:Fadrozole / Q000494:pharmacology; D046369:Finches / Q000502:physiology*; D005452:Fluoresceins; D005911:Gliosis / Q000139:chemically induced / Q000473:pathology; D007649:Ketamine / Q000494:pharmacology; D008297:Male; D018613:Microscopy, Confocal; D009410:Nerve Degeneration / Q000201:enzymology / Q000473:pathology*; D009457:Neuroglia / Q000201:enzymology*; D009930:Organic Chemicals; D014746:Vimentin / Q000096:biosynthesis
D047072:Aromatase Inhibitors; D004791:Enzyme Inhibitors; D018691:Excitatory Amino Acid Antagonists; D005452:Fluoresceins; D009930:Organic Chemicals; D014746:Vimentin; C435731:fluoro jade; D007649:Ketamine; D001141:Aromatase; D017316:Fadrozole